{"id":145656,"date":"2026-10-16T22:31:07","date_gmt":"2026-10-16T22:31:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/145656\/"},"modified":"2026-10-16T22:31:07","modified_gmt":"2026-10-16T22:31:07","slug":"novartis-discontinues-mid-stage-lupus-trial-in-latest-pipeline-setback","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/145656\/","title":{"rendered":"Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback"},"content":{"rendered":"<p>The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus.\n<\/p>\n<p>Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.Novartis has faced multiple clinical setbacks over the past several weeks, including trial failures and development discontinuations.According to data from Koyfin, 8 of the 23 analysts rate the stock a \u2018buy\u2019 or \u2018strong buy,\u2019 while 13 rate it a \u2018hold\u2019 and only two rate it \u2018sell.\u2019<\/p>\n<p>Shares of Novartis (NVS) closed little changed on Friday after the company decided to discontinue its mid-stage trial of iptacopan in lupus nephritis.<\/p>\n<p>According to a federal clinical trials registry update, the company has concluded the study over \u2018strategic considerations.\u2019 It is unclear if the discontinuation was spurred by efficacy or safety concerns.<\/p>\n<p>The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment. The company decided to conclude the study after completing the first part, as per the database.<\/p>\n<p>Iptacopan is sold under the brand name Fabhalta and is approved by the FDA for Paroxysmal Nocturnal Hemoglobinuria, Primary Immunoglobulin A Nephropathy, and C3 Glomerulopathy.<\/p>\n<p>Latest Pipeline Setback For Novartis<\/p>\n<p>Novartis has faced multiple clinical setbacks over the past several weeks. Last month, the company said that its late-stage trial of Pelacarsen, being developed as a treatment to lower elevated lipoprotein(a) or Lp(a) and reduce the risk of major cardiovascular events, missed its primary goal. The company also said that its late-stage trial of del-desiran in myotonic dystrophy type 1 (DM1) missed its primary endpoint.<\/p>\n<p>Besides the late-stage drug failures, the company also discontinued development of VHB937 in mid-September after a mid-stage study missed primary and secondary goals. \u00a0Prior to that, in August, Novartis paused multiple autoimmune and neurology trials after three fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) in patients taking its experimental therapy Rap-cel. \u00a0<\/p>\n<p>According to data from Koyfin, 8 of the 23 analysts rate the stock a \u2018buy\u2019 or \u2018strong buy,\u2019 while 13 rate it a \u2018hold\u2019 and only two rate it \u2018sell.\u2019<\/p>\n<p>How Did NVS Retail Traders React?<\/p>\n<p>On Stocktwits, retail sentiment around <a class=\"mention\" href=\"https:\/\/stocktwits.com\/symbol\/NVS\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">NVS stock<\/a> stayed within the \u2018bearish\u2019 territory over the past 24 hours, while message volume rose from \u2018low\u2019 to \u2018normal\u2019 levels.<\/p>\n<p>NVS stock has gained 9% year-to-date.\u00a0<\/p>\n<p>Read More: <a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug\/cZxKWRBRBtT\" rel=\"nofollow noopener\" target=\"_blank\">ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug<\/a><\/p>\n<p>For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n<p><a class=\"STButton_lg__XBy4m text-lg px-6 gap-2 STButton_button__ObG_J h-[--size] inline-flex flex-row items-center justify-center border rounded-full font-semibold whitespace-nowrap STButton_black-secondary__xIxs1 bg-white text-black border-secondary-button-border dark|bg-transparent dark|text-white hover|!bg-light-grey-6 dark|hover|!bg-dark-grey-5 p-2\" role=\"button\" tabindex=\"0\" type=\"button\" target=\"_blank\" rel=\"noopener nofollow\" href=\"https:\/\/news.google.com\/publications\/CAAqKQgKIiNDQklTRkFnTWFoQUtEbk4wYjJOcmRIZHBkSE11WTI5dEtBQVAB\"><img decoding=\"async\" alt=\"Follow on Google News\" src=\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/><\/a><\/p>\n<p>Subscribe to Chart Art<\/p>\n<p>The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.<\/p>\n<p><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/stocktwits.com\/about-newsroom\/\" class=\"NewsArticle_editorialLink__1BMFs hover|text-blue-ada underline w-full text-base\">Read about our editorial guidelines and ethics policy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care&hellip;\n","protected":false},"author":2,"featured_media":145657,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,1078,67322,67321,9959,60649,60648],"class_list":["post-145656","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-novartis-ag","tag-novartis-ag-shares","tag-novartis-ag-stock","tag-nvs","tag-nvs-shares","tag-nvs-stock"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117452962936258757","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/145656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=145656"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/145656\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/145657"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=145656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=145656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=145656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}